Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 3, 2016, Pages 581-589

  Muro, Kei ^a   Oh, Sang Cheul ^d   Shimada, Yasuhiro ^b   Lee, Keun Wook ^f   Yen, Chia Jui ^g,h   Chao, Yee ^i,j   Cho, Jae Yong ^e   Cheng, Rebecca ^k   Carlesi, Roberto ^k   Chandrawansa, Kumari ^k   Orlando, Mauro ^k   Ohtsu, Atsushi ^c  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d Korea University College of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Seoul National University Bundang Hospital   (South Korea)

^g NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

ⁱ NATIONAL YANG MING UNIVERSITY   (Taiwan)

^j TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^k ELI LILLY AND COMPANY   (United States)

more..

Author keywords

Far East; Gastrointestinal neoplasms; Paclitaxel; Ramucirumab; Vascular endothelial growth factor receptor 2

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PACLITAXEL; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DYSGEUSIA; EAST ASIAN; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; INSOMNIA; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERITONEUM METASTASIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; RASH; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; VENOUS THROMBOEMBOLISM; VERY ELDERLY; ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGEAL NEOPLASMS; FAR EAST; GASTROESOPHAGEAL JUNCTION; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FAR EAST; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84959094187     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13153     Document Type: Article

References (20)

1. GLOBOCAN 2012: Estimated Cancer Incidence. Stomach cancer: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=stomach/Accessed 25 Nov 2014.
2. Hsu C, Shen YC, Cheng CC, Cheng AL, Hu FC, Yeh KH. Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression. Gastric Cancer 2012; 15: 265-280.
3. Al-Refaie WB, Tseng JF, Gay G et al. The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base. Cancer 2008; 113: 461-469.
4. Kim J, Sun CL, Mailey B et al. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann. Oncol. 2010; 21: 152-160.
5. Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J. Natl. Compr. Canc. Netw. 2010; 8: 437-447.
6. Gill S, Shah A, Le N, Cook EF, Yoshida EM. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a Canadian cancer center. J. Clin. Oncol. 2003; 21: 2070-2076.
7. Price TJ, Shapiro JD, Segelov E et al. Management of advanced gastric cancer. Expert Rev. Gastroenterol. Hepatol. 2012; 6: 199-208.
8. Kim R, Tan A, Choi M, El-Rayes BF. Geographic differences in approach to advanced gastric cancer: is there a standard approach? Crit. Rev. Oncol. Hematol. 2013; 88: 416-426.
9. Hironaka S, Ueda S, Yasui H et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J. Clin. Oncol. 2013; 31: 4438-4444.
10. Shen L, Shan YS, Hu HM et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013; 14: e535-e547, Doi: 10.1016/S1470-2045(13)70436-4.
11. Bang YJ, Van Cutsem E, Feyereislova A et al.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
12. Kang JH, Lee SI, Lim DH et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J. Clin. Oncol. 2012; 30: 1513-1518.
13. Spratlin JL, Cohen RB, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 2010; 28: 780-787.
14. Fuchs CS, Tomasek J, Yong CJ et al.; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39.
15. Wilke H, Muro K, Van Cutsem E et al.; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15: 1224-1235.
16. Ohtsu A, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 2011; 29: 3968-3976.
17. Kawakami H, Okamoto I, Hayashi H, Taguri M, Morita S, Nakagawa K. Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. Eur. J. Cancer 2013; 49: 3003-3009.
18. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006; 9: 14-18.
19. Kodera Y, Ito S, Mochizuki Y et al.; Chubu Clinical Cancer Group. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric /Cancer (CCOG0302 study). Anticancer Res 2007; 27: 2667-2671.
20. Shitara K, Matsuo K, Takahari D et al. Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. Ann. Oncol. 2010; 21: 2403-2409.